Spago Nanomedical Plans Delisting to Secure Funding for Cancer Drug Development

MT Newswires · 2d ago
01:54 AM EDT, 10/23/2026 (MT Newswires) -- Spago Nanomedical (SPAGO.ST) intends to delist its shares from the Nasdaq First North Growth Market to improve access to long-term financing for its cancer treatment candidate Tumorad. The Swedish nanomedicines company said Thursday that raising capital for a planned phase 2a trial on acceptable terms would be difficult while listed. The proposal requires shareholder approval at a Nov. 19 meeting, with holders of 65% of shares and votes having indicated their support. Spago expects to submit its delisting application no earlier than Jan. 25, 2027, with the last trading day anticipated in February 2027.